SG11201708158PA - Composition for suppressing muscular fatty change - Google Patents

Composition for suppressing muscular fatty change

Info

Publication number
SG11201708158PA
SG11201708158PA SG11201708158PA SG11201708158PA SG11201708158PA SG 11201708158P A SG11201708158P A SG 11201708158PA SG 11201708158P A SG11201708158P A SG 11201708158PA SG 11201708158P A SG11201708158P A SG 11201708158PA SG 11201708158P A SG11201708158P A SG 11201708158PA
Authority
SG
Singapore
Prior art keywords
composition
fatty change
suppressing muscular
muscular
suppressing
Prior art date
Application number
SG11201708158PA
Inventor
Yuta Otsuka
Noriyuki Kanzaki
Shuichi Machida
Original Assignee
Suntory Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Holdings Ltd filed Critical Suntory Holdings Ltd
Publication of SG11201708158PA publication Critical patent/SG11201708158PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
SG11201708158PA 2015-04-27 2016-04-22 Composition for suppressing muscular fatty change SG11201708158PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015090580 2015-04-27
PCT/JP2016/062700 WO2016175136A1 (en) 2015-04-27 2016-04-22 Composition for suppressing muscular fatty change

Publications (1)

Publication Number Publication Date
SG11201708158PA true SG11201708158PA (en) 2017-11-29

Family

ID=57198430

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201909412R SG10201909412RA (en) 2015-04-27 2016-04-22 Composition for suppressing muscular fatty change
SG11201708158PA SG11201708158PA (en) 2015-04-27 2016-04-22 Composition for suppressing muscular fatty change

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201909412R SG10201909412RA (en) 2015-04-27 2016-04-22 Composition for suppressing muscular fatty change

Country Status (8)

Country Link
US (1) US20180104269A1 (en)
JP (1) JP7013238B2 (en)
CN (1) CN107530320A (en)
CA (1) CA2982645C (en)
HK (1) HK1246182A1 (en)
SG (2) SG10201909412RA (en)
TW (1) TW201713330A (en)
WO (1) WO2016175136A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018087175A (en) * 2016-11-30 2018-06-07 花王株式会社 Muscular atrophy inhibitor
SG11201907472QA (en) * 2017-03-10 2019-09-27 Suntory Holdings Ltd Composition for inhibiting myofibrosis
WO2019208627A1 (en) * 2018-04-27 2019-10-31 サントリーホールディングス株式会社 Composition for preventing decrease in muscle mass, preventing decrease in muscular power, increasing muscle mass or enhancing muscular power
CN114745967A (en) * 2019-11-27 2022-07-12 三得利控股株式会社 Composition for inhibiting decrease in muscle mass, inhibiting decrease in muscle strength, increasing muscle mass or increasing muscle strength
CN114958730A (en) * 2022-04-22 2022-08-30 南京农业大学 Muscle stem cell proliferation medium, differentiation medium and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100441590C (en) * 2006-03-10 2008-12-10 中山大学 Compounds like quercetol and metal complex of their glycosides and uses
JP2008255075A (en) * 2007-04-09 2008-10-23 Daidoo Dorinko Kk Improving agent for vessel endothelium function and health food
JP2013126951A (en) * 2010-03-01 2013-06-27 Kyushu Univ Muscular atrophy inhibitor
JP2014015428A (en) * 2012-07-10 2014-01-30 Kao Corp Satellite cell differentiation promoter
JP2014037387A (en) * 2012-08-18 2014-02-27 Kobe Gakuin Therapeutic agent for muscular dystrophy
SG11201608760WA (en) * 2014-04-28 2016-11-29 Suntory Holdings Ltd Muscle atrophy inhibitor containing quercetin glycoside

Also Published As

Publication number Publication date
CN107530320A (en) 2018-01-02
TW201713330A (en) 2017-04-16
JPWO2016175136A1 (en) 2018-02-15
SG10201909412RA (en) 2019-11-28
JP7013238B2 (en) 2022-01-31
HK1246182A1 (en) 2018-09-07
WO2016175136A1 (en) 2016-11-03
US20180104269A1 (en) 2018-04-19
CA2982645C (en) 2024-02-13
CA2982645A1 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
GB201512030D0 (en) Composition
GB201521507D0 (en) Composition
GB201506827D0 (en) Composition
HK1246182A1 (en) Composition for suppressing muscular fatty change
LT3273947T (en) Composition for ocular health
GB201515640D0 (en) Composition
GB201506830D0 (en) Composition
GB201506829D0 (en) Composition
GB201506825D0 (en) Composition
GB201517546D0 (en) Composition
GB201506828D0 (en) Composition
GB201518348D0 (en) Composition
GB201514585D0 (en) Composition
GB201511697D0 (en) Composition
GB201509044D0 (en) Composition
GB201505520D0 (en) Composition
GB201504665D0 (en) Composition
PL3347444T3 (en) Fat compositions
PL3344070T3 (en) Edible composition
GB201519327D0 (en) Composition
GB201515639D0 (en) Composition
GB201508722D0 (en) Composition
GB201506826D0 (en) Composition
GB201521384D0 (en) Composition
GB201520125D0 (en) Composition